ADVANCE ONLINE PUBLICATION

RESEARCH HIGHLIGHTS

One drug, five targets

Haipeng Fu , Alan R. Saltiel

Division of Endocrinology and Metabolism, Departments of Medicine and Pharmacology, University of California San Diego, San Diego, CA, USA
* Correspondence: Alan R. Saltiel(asaltiel@health.ucsd.edu)

In a recent study in Nature, Liskiewicz and colleagues described GLP-1–GIP–lanifibranor conjugate that links incretin receptor agonism to targeted PPAR activation and improves obesity and diabetes in mice.

https://doi.org/10.1038/s41422-026-01271-3

FULL TEXT | PDF

Browse 58